Sex hormones influence survival of patients with metastatic urothelial carcinoma undergoing immune checkpoint therapy

Sex hormones influence survival of patients with metastatic urothelial carcinoma undergoing immune checkpoint therapy

Abstract Introduction Clinical trials investigating efficacy of immune checkpoint inhibitors (ICI) revealed sex-specific divergent outcomes in urothelial cancer (UC), suggesting that sex hormones might play an important role in gender-specific dimorphisms of response upon ICI. However, further clini...

Full description

Bibliographic Details
Main Authors:	Andrea Katharina Lindner, Felizian Lackner, Piotr Tymoszuk, Dominik Andreas Barth, Andreas Seeber, Florian Kocher, Bettina Toth, Margarethe Hochleitner, Martin Pichler, Renate Pichler
Format:	Article
Language:	English
Published:	BMC 2023-06-01
Series:	Biology of Sex Differences
Subjects:	Metastatic urothelial carcinoma Immunotherapy Overall survival Sex hormones Gonadotropins Prognostic
Online Access:	https://doi.org/10.1186/s13293-023-00522-x

Similar Items

Chemotherapy of Locally Advanced or Metastatic Urothelial Cell Carcinoma: Monocentric Real-Life Data
by: Fischer C, et al.
Published: (2020-06-01)

Progress in immune checkpoint inhibitor-based combined regimens in the treatment of metastatic urothelial carcinoma
by: Liu Jianbing, Yue Zhongjin, Shang Panfeng, Liu Yating, Chang Hong
Published: (2023-09-01)

Biomarkers of the Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
by: Siteng Chen, et al.
Published: (2020-08-01)

Fine needle aspiration cytology of metastatic urothelial carcinoma: Study of seven cases with review of literature
by: Gagandeep Kaur, et al.
Published: (2012-01-01)

Optimization of postoperative surveillance protocols in upper tract urothelial cancer: A retrospective cohort study
by: Andrea Katharina Lindner, et al.
Published: (2023-03-01)

Checkpoint Inhibition for Metastatic Urothelial Carcinoma After Chemotherapy—Real-World Clinical Impressions and Comparative Review of the Literature
by: Christian Fuhrmann, et al.
Published: (2020-05-01)

Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma after Discontinuing Pembrolizumab as a Second-Line Treatment: A Retrospective Multicenter Real-World Cohort Study
by: Toyohiro Yamada, et al.
Published: (2022-09-01)

Superior vena cava syndrome due to metastasis from urothelial cancer: A case report and literature review
by: Hironobu Wakeda, et al.
Published: (2013-01-01)

Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma
by: Faiena I, et al.
Published: (2018-01-01)

Construction and verification of a novel hypoxia-related lncRNA signature related with survival outcomes and immune microenvironment of bladder urothelial carcinoma by weighted gene co-expression network analysis
by: Dawei Cai, et al.
Published: (2022-08-01)

Prognostic Value and Clinical Significance of FGFR Genomic Alterations (GAs) in Metastatic Urothelial Cancer Patients
by: Elena Sevillano Fernández, et al.
Published: (2022-08-01)

Complete Response to Enfortumab Vedotin in a Hemodialysis Patient with Metastatic Urothelial Carcinoma: A Case Report
by: Bunpei Isoda, et al.
Published: (2023-06-01)

Efficacy of pembrolizumab rechallenge for metastatic urothelial carcinoma
by: Nobutaka Nishimura, et al.
Published: (2022-09-01)

Histology of variants of urothelial carcinoma of the bladder: a Moroccan series of 39 cases
by: Amine Saouli, et al.
Published: (2021-01-01)

Efficacy and Safety of Programmed Death-1/Programmed Death-Ligand 1 Inhibitor for Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis
by: Pei-Fei Liao, et al.
Published: (2023-11-01)

A case of acute lymphocytic gastritis related to treatment with pembrolizumab for metastatic urothelial carcinoma
by: Yousuke Fukiishi, et al.
Published: (2023-03-01)

The prognostic significance of histologic variant on survival outcomes in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitor therapy
by: Tsung-Han Tsai, et al.
Published: (2023-09-01)

Efficacy of Vinflunine for Patients with Metastatic Urothelial Cancer after Immune Checkpoint Inhibitor Pretreatment—A Retrospective Multicenter Analysis
by: Felix Riedel, et al.
Published: (2022-06-01)

A Rare Case Report of Metastatic Urothelial Carcinoma to Skull with Significant Reossification after Pembrolizumab
by: Yung-Hao Liu, et al.
Published: (2021-09-01)

Targeted Treatment of Locally Advanced and Metastatic Urothelial Cancer: Enfortumab Vedotin in Context
by: Hoffman-Censits J, et al.
Published: (2022-12-01)

First line therapy of metastatic urothelial bladder cancer
by: Lorena Stamičar, et al.
Published: (2021-01-01)

Prognostic Significance of Organ-Specific Metastases in Patients with Metastatic Upper Tract Urothelial Carcinoma
by: Antonio Tufano, et al.
Published: (2022-09-01)

Diagnostic and Prognostic Roles of GATA3 Immunohistochemistry in Urothelial Carcinoma
by: Daeseon Yoo, et al.
Published: (2023-08-01)

Lynch Syndrome: Its Impact on Urothelial Carcinoma
by: Andrea Katharina Lindner, et al.
Published: (2021-01-01)

Role of microRNAs in regulation of WNT signaling pathway in urothelial and prostate cancers
by: Mehdi Montazer, et al.
Published: (2022-06-01)

Metastatic Urothelial Tumor Progression Following First Line Chemotherapy: Prognostic Factors and Importance of Second Line Chemotherapy
by: Mohammad S. Ma’koseh, et al.
Published: (2018-07-01)

Poor prognosis of urothelial carcinoma in patients presented with persistent paraneoplastic leukocytosis with anemia
by: Syah Mirsya Warli, et al.
Published: (2022-01-01)

Translation of the 27-gene immuno-oncology test (IO score) to predict outcomes in immune checkpoint inhibitor treated metastatic urothelial cancer patients
by: Robert S. Seitz, et al.
Published: (2022-08-01)

Disease control with prior platinum-based chemotherapy is prognostic for survival in patients with metastatic urothelial cancer treated with atezolizumab in real-world practice
by: Mencinger Marina, et al.
Published: (2021-05-01)

Prognostic and Predictive Factors in Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors: A Review of the Current Evidence
by: Sara Elena Rebuzzi, et al.
Published: (2021-11-01)

Real-World Insights into Efficacy and Safety of Enfortumab Vedotin in Japanese Patients with Metastatic Urothelial Carcinoma: Findings, Considerations, and Future Directions
by: Yuki Endo, et al.
Published: (2024-01-01)

Pretreatment Neutrophil-Lymphocyte Ratio as a Predictor in Bladder Cancer and Metastatic or Unresectable Urothelial Carcinoma Patients: a Pooled Analysis of Comparative Studies
by: Shuiqing Wu, et al.
Published: (2018-04-01)

Comparison of full-dose gemcitabine/cisplatin, dose-reduced gemcitabine/cisplatin, and gemcitabine/carboplatin in real-world patients with advanced urothelial carcinoma
by: Kazuma Sugimoto, et al.
Published: (2022-11-01)

Case report: Urothelial carcinoma of the renal pelvis with trophoblastic differentiation: A rare case report and review of literature
by: Zhuo Wang, et al.
Published: (2023-02-01)

Profiling of extracellular vesicles of metastatic urothelial cancer patients to discover protein signatures related to treatment outcome
by: Kristina Viktorsson, et al.
Published: (2022-10-01)

Efficacy and Safety of Chemotherapy Regimens in Advanced or Metastatic Bladder and Urothelial Carcinomas: An Updated Network Meta-Analysis
by: Hong-Chen Qu, et al.
Published: (2020-01-01)

Gemcitabine and docetaxel as second-line chemotherapy in elderly patients with metastatic urothelial carcinoma: a retrospective analysis
by: Naiki T, et al.
Published: (2018-09-01)

Identification of 9-Core Immune-Related Genes in Bladder Urothelial Carcinoma Prognosis
by: Lei Na, et al.
Published: (2020-07-01)

Maintenance avelumab in a patient with metastatic urothelial carcinoma on hemodialysis: A case report
by: Sarah Belay, et al.
Published: (2022-12-01)

Cost-Effectiveness of Immune Checkpoint Inhibitors in Urothelial Carcinoma—A Review
by: Arman S. Walia, et al.
Published: (2021-12-01)